TerminatedPhase 2NCT00335140
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Studying Primary central nervous system lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Lode J. Swinnen, MD, M.D., Ph.DSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Intervention
- Rituximab(biological)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2015
Study locations (30)
- Stanford Cancer Center, Stanford, California, United States
- University of Florida Shands Cancer Center, Gainesville, Florida, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
- Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States
- McFarland Clinic, PC, Ames, Iowa, United States
- Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
- Mercy Medical Center - Sioux City, Sioux City, Iowa, United States
- St. Luke's Regional Medical Center, Sioux City, Iowa, United States
- Hospital District Sixth of Harper County, Anthony, Kansas, United States
- Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States
- Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States
- Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States
- Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States
- Cancer Center of Kansas-Independence, Independence, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00335140 on ClinicalTrials.govOther trials for Primary central nervous system lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07555561Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System LymphomaBeijing Boren Hospital
- RECRUITINGPHASE3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd
- RECRUITINGPHASE2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPHASE2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho
- RECRUITINGPHASE2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06931652Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabThe Lymphoma Academic Research Organisation
See all trials for Primary central nervous system lymphoma →